Research Article

A Preliminary Evaluation of the Physiological Mechanisms of Action for Sleep Restriction Therapy

Table 4

Means (M) and standard deviations (SD) of polysomnographic data.

Sleep variables Evaluation periods
Baseline
(BN2)
M (SD)
Treatment Posttreatment
M (SD)
Follow-up
M (SD)
1st nights
(TR3, TR4)
M (SD)
Sleep stabilized
M (SD)

Treatment responders ( = 3, except at follow-up = 2)
SOL (min)51.8 (69.9)13.0 (15.5)7.7 (7.6)14.8 (11.1)46.0 (65.0)
WASO (min)55.1 (25.9)26.2 (14.3)17.5 (17.5)42.0 (56.9)32.5 (29.9)
TST (min)330.1 (80.5)306.7 (32.6)348.5 (18.6)350.9 (37.3)371.5 (29.4)
SE (%)74.8 (16.3)88.2 (4.4)92.5 (4.6)86.3 (11.6)85.2 (14.5)
% stage 252.1 (6.4)49.9 (6.9)46.5 (4.9)55.3 (6.8)54.7 (8.1)
% stages 3-421.9 (5.1)23.7 (7.5)24.6 (3.9)14.0 (19.8)15.6 (8.1)
% REM 17.8 (5.0)22.7 (5.5)25.2 (2.8)27.5 (4.2)26.1 (2.4)

Nonresponders ( = 2 for baseline and 1st nights, then, = 1)
SOL (min)17.1 (13.0)18.0 (7.7)6.3 (6.7)5.3 (0.4)28.0 (24.5)
WASO (min)115.5 (73.6)26.3 (8.5)64.3 (27.9)55.8 (2.5)64.8 (15.2)
TST (min)302.4 (85.1)289.1 (39.2)285.0 (25.5)312.8 (1.1)385.8 (40.7)
SE (%)68.8 (14.9)86 (3.5)79.5 (6.4)83.0 (0.0)80.0 (8.5)
% stage 256.0 (5.3)54.8 (8.7)70.1 (1.6)56.0 (4.9)63.0 (1.8)
% stages 3-415.8 (4.4)18.7 (10.2)2.0 (1.7)10.5 (3.6)6.2 (5.1)
% REM 21.9 (8.0)21.2 (5.3)24.9 (0.3)32.2 (2.0)27.7 (6.9)

BN2: baseline night 2; TR3: the third night in lab and the first of treatment; TR4: the fourth night in lab and the second of treatment; SOL: sleep-onset latency; WASO: wake time after sleep-onset; TST: total sleep time; SE: sleep efficiency; REM: rapid eye movement; min: minutes.